HealthcareOn the MoveCuris (NASDAQ:CRIS -4.5%) trades rather violently after the FDA approves Erivedge for use to...Jan. 30, 2012 11:21 AM ETCuris, Inc. (CRIS) StockBy: Clark Schultz, SA News EditorCuris (NASDAQ:CRIS -4.5%) trades rather violently after the FDA approves Erivedge for use to treat adult patients with skin cancer. Shares spiked up 7%, then sank 14% before quickly heading back north.Recommended For YouMore Trending NewsSee More »About CRIS StockSymbolLast Price% Chg1D5D1M6M1Y5Y10YMarket CapPEYield (TTM)Rev Growth (YoY)Prev. CloseCompare to PeersRelated StocksSymbolLast Price% ChgCRIS--Curis, Inc.Trending AnalysisTrending News